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Background: Large genomic rearrangements (LGRs) ac-
count for a substantial proportion of the BRCA1 disease-
causing changes, or variations, identified in families
with hereditary breast/ovarian cancer [HB(O)C]. Great
differences in the spectrum and prevalence of BRCA1
LGR have been observed among populations. Here we
report the first comprehensive analysis of BRCA1 LGRs
conducted in Spain.
Methods: We used multiplex ligation-dependent probe
amplification (MLPA) to screen for BRCA1 LGRs in the
index case individuals of 384 HB(O)C families who
previously tested negative for BRCA1 and BRCA2 point
variations, small insertions, and deletions. An alterna-
tive set of MLPA probes, long-range PCR, and real-time
PCR were used to confirm positive results.
Results: We have identified 8 different BRCA1 rear-
rangements (del exon 1–24, del exon 8–13, del exon
11–15, del exon 14, dup exon 19–20, dup exon 20, exon
21–22 amplification, and del exon 23–24). With the
exception of del exon 8–13, they are novel alterations.
Overall, BRCA1 LGRs explain 1.4% of the Spanish
HB(O)C families, and they account for 8.2% of all
BRCA1 pathogenic variations identified in our study
population. BRCA1 genetic variants affecting hybridiza-
tion of commercially available MLPA probes are very
rare in our population.
Conclusions: Screening for BRCA1 LGRs should be
mandatory in Spanish HB(O)C families. A high propor-
tion of country-specific rearrangements are scattered
along the gene. MLPA is a robust method to screen for
LGRs in our population. MLPA analysis of positive
samples with an alternative set of probes, together with
long-range PCR and real-time PCR, is a feasible ap-
proach to confirm results in cases in which LGR break-
points have not been characterized.
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BRCA1 (OMIM No 113705)9 was the first breast cancer
susceptibility gene identified. Several studies have re-
ported the presence of BRCA1 germ-line disease-causing
changes, or variations, in breast/ovarian cancer families
from different ethnicities and geographical areas of the
world. The Spanish Consortium for Hereditary Breast and
Ovarian Cancer performed a comprehensive analysis of
BRCA1 germ-line variations in Spanish families with
breast/ovarian cancer. As reported in many other popu-
lations, the highest frequency of variations was found in
families with both breast and ovarian cancer cases
(52.1%). The frequency was much lower in site-specific
families with breast cancer (15.4%). Relevant findings of
that study were the high proportion of variations that
appear to be unique to Spaniards (42%) and the existence
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of recurrent variations associated with the geographical
origin of the families (1 ).
In all populations tested, the observed frequency of
BRCA1 variations in high-risk breast/ovarian cancer fam-
ilies was consistently lower than predicted by linkage
analysis (2 ). This finding suggests that methods for scan-
ning variations fail to detect all BRCA1 germ-line defects.
For instance, large genomic rearrangements (LGRs)10 are
not detectable by current PCR-based methods, perhaps
explaining the discrepancy between linkage analysis and
genetic testing. In support of this view, it has been
proposed that the genetic structure of BRCA1, with nu-
merous intragenic alu repeats (3 ) and 1 BRCA1 pseudo-
gene 30 kb upstream (4, 5), might render this locus
particularly prone to LGRs. Indeed, different studies have
demonstrated the existence of germ-line LGRs involving
either alu repeats (6–10) or the BRCA1 pseudogene (11 ).
At least one LGR has been reported in which neither alu
repeats nor the BRCA1 pseudogene were involved (12 ).
Although LGRs do not fully explain the observed
discrepancy between BRCA1 linkage analysis and varia-
tion screening, they account for a substantial proportion
of BRCA1 variations in tested populations. Unfortunately,
the detection of heterozygous LGRs remains challenging
(13 ). The analysis may become straightforward in certain
populations in which strong founder effects are present.
For instance, 2 alu-mediated deletions, involving exons 13
and 22, account for a substantial proportion of all BRCA1
variations found in Dutch families with high risk for
breast/ovarian cancer (6 ) but are not present in other
populations. Several approaches have been used to detect
LGRs in the BRCA1 locus, including Southern blot (6–8),
long-range PCR (12 ), fluorescence in situ hybridization-
based methods (14 ), and real-time PCR (15 ), but studies
directly comparing the detection limit of those techniques
are not available.
In recent years, multiplex ligation-dependent probe
amplification (MLPA) has emerged as a powerful method
to screen LGRs in a large number of samples (16–18). We
investigated the clinical relevance of the results of the
Spanish Consortium for Hereditary Breast and Ovarian
Cancer analysis of BRCA1 LGRs in the Spanish popula-
tion and tested the feasibility of MLPA for scanning for
BRCA1 LGRs in a genetic diagnostic laboratory.
Materials and Methods
Hereditary breast and/or ovarian cancer HB(O)C fami-
lies—those families in which a minimum of 3 patients
with breast and/or ovarian cancer were present in 2
generations of the same parental branch—were identified
through family cancer services throughout Spain. In-
formed consent was obtained from all study participants.
The contributing centers were Hospital Clı´nico San Carlos
in Madrid (HCSC), Hospital de la Santa Creu i Sant Pau in
Barcelona (HSP), Instituto de Biologı´a y Gene´tica Molec-
ular-Universidad de Valladolid in Valladolid (IBGM),
Centro Nacional de Investigaciones Oncolo´gicas in Ma-
drid (CNIO), Unidad de Medicina Molecular in Santiago
de Compostela (UMM-FPGMX), Centro de Investigacio-
nes del Ca´ncer-Universidad de Salamanca in Salamanca
(CIC-US), and Institut Catala` d’Oncologia in Barcelona
(ICO).
Before LGRs analysis, all families were tested for the
presence of point variations at the BRCA1 and BRCA2
genes. In each family, variation scanning, including the
full coding sequence and intron/exon boundaries of both
genes, was carried out in the index case (usually the
youngest affected member). Methods have been described
previously (1 ) and are available on request.
A consecutive series of 417 HB(O)C families were
identified during the period 1998–2004 through the
HCSC, HSP, and IBGM centers. After conventional vari-
ation scanning, 67 BRCA1- and 65 BRCA2-related families
were identified, and 285 families remained negative. Of
this negative group, 55 were breast and ovarian cancer
families (HBOC) and 230 were site-specific breast cancer
families (HBC). The study performed in these families is
referred to throughout the text as study I.
Other participant centers tested only those negative
HB(O)C families with additional features of hereditary
cancer, such as bilateral cases, concomitant breast and
ovarian cancer in one patient, or very early age at diag-
nosis (35 years). A total of 99 such families (32 HBOC
and 67 HBC families) were tested. The study is referred to
throughout the text as study II.
All participating centers used MLPA amplification to
detect LGRs at the BRCA1 locus. MLPA was performed
with the BRCA1 P002 probe mix assay according to the
instructions provided by the manufacturer (MRC Hol-
land). In all positive samples, additional analysis with the
alternative set of probes P087 (MRC Holland) was per-
formed to confirm results. Separation and relative quan-
tification of picks was obtained with ABI-310 or ABI-3100
genetic analyzers (Applied Biosystems). Variations in
peak areas were evaluated by cumulative comparison of
samples from the same experiment by GeneScan software
(Applied Biosystems). For statistical analysis, the individ-
ual peak areas were transferred into an Excel data sheet,
and the protocols for the final assessment of allele dosage
(calculating the relative peak areas) were used as de-
scribed by the manufacturer (www.mrc-holland.com).
Genomic amplifications were confirmed by real-time
10 Nonstandard abbreviations: LGRs, large genomic rearrangements;
MLPA, multiplex ligation-dependent probe amplification; HB(O)C, hereditary
breast and/or ovarian cancer; HCSC, Hospital Clı´nico San Carlos in Madrid;
HSP, Hospital de la Santa Creu i Sant Pau in Barcelona; IBGM, Instituto de
Biologı´a y Gene´tica Molecular-Universidad de Valladolid in Valladolid; CNIO,
Centro Nacional de Investigaciones Oncolo´gicas in Madrid; UMM-FPGMX,
Unidad de Medicina Molecular in Santiago de Compostela; CIC-US, Centro de
Investigaciones del Ca´ncer-Universidad de Salamanca in Salamanca; ICO,
Institut Catala` d’Oncologia in Barcelona; HBOC, breast and ovarian cancer
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quantitative PCR in a LightCycler (Roche). All primers are
available on request. Reactions were performed in 10 L
final volume with LightCycler-FastStart DNA Master
SYBR Green I (Roche) and uracil DNA glycosilase (0.25
U). Dilutions of a control DNA were used to construct
calibration curves for exons 10,19,20,21, and 22. Exon 10
was used as reference of wild-type allele dosage. Quanti-
fication of the suspected amplified exons relative to the
reference exon was performed in positive samples and in
control DNA by comparing crossing points with Light
Cycler software versio´ns 3.5 (Roche).
Deletions were confirmed by long-range PCR per-
formed with LA PCR assay v2 (Takara Bio Inc), according
to the supplier instructions, followed by restriction-frag-
ment analysis.
Results
In addition to the 67 BRCA1-related families previously
detected by conventional scanning methods, 6 families
with LGRs at the BRCA1 locus were identified in study I.
BRCA1 LGRs account for 1.4% of unselected HB(O)C
families (6/417), 2.1% of unselected HB(O)C families
without detectable point variations in BRCA1 and BRCA2
(6/285), and 8.2% of all BRCA1 pathogenic variations
identified in study I (6/73). Five additional families with
BRCA1 LGRs were identified in study II.
The prevalence of BRCA1 LGRs according to clinical
criteria is shown in Table 1. Overall, we found a higher
proportion of rearrangements in HBOC families (7/87)
than in HBC families (4/297). The finding was statistically
significant (8% vs 1.3%; odds ratio 6.41; 95% confidence
interval, 1.63–26.8, P  0.0037). The spectrum of alter-
ations is outlined in Table 2. We have identified 8 differ-
ent BRCA1 LGRs. One of these, del exon 8–13, has been
reported previously in a French family (8 ). The remaining
7 are novel alterations not reported in other populations.
Different strategies were used to characterize the
breakpoints of internal deletions. The index case of family
CNIO-115 had an MLPA profile suggestive of a deletion
comprising exons 8–13. A BRCA1 deletion of exons 8–13
had been described previously in a French family (8 ). We
used specific PCR primers (8 ) to confirm that our family
carried the same rearrangement, encompassing nucleo-
tides 26967 to 50729 inclusive (GenBank accession no.
L78833).
Family HCSC 221 had an MLPA profile suggestive of
an exon 14 deletion in 2 affected women. One of the
women had breast cancer, diagnosed at 32 years, the other
had ovarian cancer, diagnosed at 42 years. No other
family member was participating in the study. For both
women, we performed a long-range PCR to amplify the
BRCA1 gene from exon 13 to exon 15. A fragment of3 kb
was amplified in DNA from both affected women. The
expected 8.2-kb fragment was not observed, probably
because of preferential amplification of the shorter frag-
ment. However, the 8.2-kb fragment was amplified in
control DNA. Digestion of the specific 3-kb PCR product
by different restriction enzymes showed that the deletion
breakpoints comprised a Bgl II fragment of 6715 bp (data
not shown). Different sets of primers were designed in
this region. We finally designed a forward primer anneal-
ing in intron 13 (TTCTGGAGATCTGTAACTG) and a
reverse primer annealing in intron 14 (TATGTTAGAAT-
CAGATCTC), which amplified a 750-bp fragment con-
taining the breakpoints. After sequencing, the deletion
was shown to encompass nucleotides 47840 to 52790. The
breakpoints involved alu sequences, because it has been
reported for other BRCA1 deletions (19 ). Family CIC-US1
has an MLPA profile suggestive of an exon 14 deletion. A
PCR with primers intron 13fw and intron 14rev confirmed
that this family carried the same rearrangement.
The index case of family IBGM 211 showed an MLPA
suggestive of a deletion spanning exons 11 to 15. A PCR
was performed, with a forward primer annealing in
intron10 (ctgcatacatgtaactag) and a reverse primer anneal-
ing in intron 16 (agtcattagggagatacata). In control individ-
uals, no product was generated (the expected fragment of
25.1 kb is probably too long to be amplified in our
conditions), but a 2-kb fragment was generated in this
patient, supporting the presence of an internal deletion
spanning 23 kb. Both strands of the 2-kb fragment were
sequenced by primer walking. The forward sequence was
compatible with a deletion encompassing nucleotides
33450 to 56562 (GenBank accession no. L78833). Because
of the presence of repetitive sequences, breakpoints could
not be confirmed by reverse sequencing.
We have not been able to characterize the breakpoints
in the remaining cases. However, we have obtained
additional evidence supporting the presence of a rear-
rangement. The index case of family HCSC 159 had an
MLPA profile compatible with a deletion encompassing
the last 2 exons of the gene (23 and 24). Nine female
relatives were tested. The abnormal profile was detected
in all affected women (2 each of breast and 2 ovarian
cancer) but in only 1 woman (age 28 years) of 5 healthy
women tested. We performed long-range PCR with a
forward primer located in exon 22 (tgattttacatctaaatgtc)
and a reverse primer located 9.4 kb downstream of the
stop codon (aagtgaagcggtgatttgctctc). The expected
13.1-kb fragment was not amplified in control DNA, but
an 6-kb fragment was consistently observed in DNA
with an abnormal MLPA profile. Further analysis with
Table 1. BRCA1 LGR in families previously tested negative
for BRCA1/2 variations.
Ascertainment Phenotype n BRCA1 LGR Frequency, %
Study I HBOC 55 4 7.2
HBC total 230 2 0.9
285 6 2.1
Study II HBOC 32 3 9.3
HBC total 67 2 3.0
99 5 5.1
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restriction enzymes showed that an XmaI-HindIII frag-
ment of 7.6 kb, encompassing exons 23 and 24, was lost.
In both IBGM 98 and IBGM 107 families, the index case
showed an MLPA profile compatible with amplification
of exons 21 and 22. In family IBGM 98, the index case
showed an allele dosage of 2.84 and 2.65 for exons 21 and
22, respectively. The index case of family IBGM107
showed an allele dosage of 2.72 and 2.77. The data were
compatible with the presence of 3 or 4 extra copies of both
exons in the families. Additional analysis by real-time
quantitative PCR indicated the presence of a minimum of
4 extra copies of both exons, but neither the precise
number of extra copies nor the size of the amplicon has
been fully characterized, and we cannot rule out the
possibility that the families carried different rearrange-
ments.
Similarly, MLPA allele dosage and real-time quantita-
tive PCR confirmed the presence of 1 extra copy of exons
19 and 20 in family CIC-US 2, and 1 extra copy of exon 20
in families CIC-US 3 and CIC-US 4.
The index case of family HSP-198 showed an MLPA
profile suggestive of a deletion involving the complete
BRCA1 gene. This alteration was confirmed to segregate
with the disease in the family. It was detected in 4 female
relatives; 1 with ovarian cancer case diagnosed at 41
years, 1 with breast cancer diagnosed at 43 years, 1 with
endometrial cancer diagnosed at 41 years, and 1 healthy
woman at 45 years. The alteration was not present in a
50-year-old healthy woman.
Finally, it is worth mentioning that only 1 of 348
samples tested with the P002 probe set carried a DNA
variant hampering probe hybridization. The BRCA1 vari-
ant 5214 C to T, a missense variation (R1699W) of uncer-
tain pathogenic significance, is located at the ligation site
of the exon 18 probe (U14680, 5213–5214). MLPA analysis
with the alternative P087 probe set, which has a ligation
site 41 nucleotides downstream (U14680, 5254–5255) dis-
carded the presence of an exon 18 deletion.
Discussion
We conducted independent analysis in 2 family series
selected with different criteria. Following the guidelines
of our Consortium, HB(O)C families with a minimum of 3
breast and/or ovarian cancer cases diagnosed in 2 gener-
ations of 1 parental branch are eligible for genetic testing,
irrespectively of the age at diagnosis or the presence of
additional features of hereditary cancer. Study I was
conducted in a consecutive series to estimate the actual
prevalence of LGRs in such families. Study II was per-
formed in a nonconsecutive group of HB(O)C families
with additional features of hereditary cancer. The latter
study was conducted in those laboratories in which
cost-effectiveness was a priority.
Study I showed a 2.1% prevalence of BRCA1 LGRs in
Spanish HB(O)C families previously testing negative for
point variations and small insertions/deletions in BRCA1
and BRCA2. A recent study performed in Australian and
New Zealand families found BRCA1 LGRs in 2.2% of the
negative families (19 ). The entry criteria in the latter study
were similar to those in study I. LGRs have been reported
in 6% of German (20 ), 5.9% of French (21 ), and 4.4% of UK
(22 ) BRCA1/2–variation-negative families. However,
without exception, these studies were performed in fam-
ilies with additional hereditary cancer features, such as
bilateral disease or early age at diagnosis. Therefore, these
studies cannot be directly compared to study I. In fact,
selection criteria in these studies were similar to those in
study II, in which we found LGRs in 5.1% of the negative
families.
The fact that different studies report different preva-
lences of BRCA1 LGRs may reflect the different genetic
backgrounds of participants. This conclusion is not
Table 2. Germ-line BRCA1 genomic rearrangements found in Spanish families with HB(O)C.









HSP 198 I Del Ex1–24 Yes nd HBOC no
CNIO-115 II Del Ex8–13 nd Sequencing 26967–50729 HBOC yes
IBGM 211 I Del Ex11–15 nd Sequencing 33450–56562b HBOC no
HCSC 221 I Del Ex14 Yes Sequencing 47840–52790 HBOC no
CIC-US 1 II Del Ex14 Yes Sequencing 47840–52790 HBOC no
CIC-US 2 II Dup Ex19–20 Yes Real-time PCR nd HBC no
CIC-US 3 II Dup Ex20 Yes Real-time PCR nd HBC no
CIC-US 4 II Dup Ex20 Yes Real-time PCR nd HBOC no
IBGM 98 I Ex21–22 Amplification nd Real-time PCR nd HBC no
IBGM 107 I Ex21–22 Amplification nd Real-time PCR nd HBC no
HCSC 159 I Del Ex23–24 Yes Long-range PCR nd HBOC no
nd, not determined.
a Probe set P002 and Probe set P087.
b 2 See text for further details.
c 3 GenBank accession no. L78833.
d 4 Bibliographic search December 2005.
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straightforward, however, because other variables may
explain such differences. Methodology is unlikely to be a
major factor, because the same commercially available
MLPA assay is used in most of the cited reports (the
French study relies on a complete different approach,
based on fluorescent hybridization of DNA probes on
combed DNA). Study size may be relevant. For instance,
the German report was conducted in 75 families, and the
Australian/New Zealand study included 312. However,
we think that the most likely explanation for differences is
selection bias. There is no consensus on which clinical
criteria should be followed in the selection of HB(O)C
families. As a result, studies performed in different coun-
tries select families on the basis of different clinical
criteria. The effect of selection bias (for instance, a consec-
utive series vs selection of families with high-risk fea-
tures) on prevalence may be strong, as our own data
reveal (study II compared with study I). For this reason, it
is often meaningless to compare prevalence among
studies.
In our view, the proportion of variations that LGRs
account for in a given population is more informative.
First, this rate is independent of selection bias (assuming
that LGRs confer cancer risk similar to that of point
variations) and can therefore be directly compared among
studies. Second, it will indicate whether it may be more
cost effective to perform LGR testing before or after
conventional screening. According to study I, 8.2% of the
BRCA1 variations present in Spanish HB(O)C families are
LGRs. This rate is very similar to that of German (8%),
French (9.5%), and US (8%) populations and slightly
lower than the UK (13.5%) or Australia/New Zealand
(14.9%) populations (6, 19–22). A higher proportion of
LGRs has been found in Holland, but this is attributable to
the del 13 and del 22 founder variations, which account
for 24% of all BRCA1 variations in this population (17 ).
The highest proportion of LGRs found so far was in a
North Italian population (40%), although the sample size
in this study was small (17 ).
The percentage of LGRs detected in our study supports
the view that screening for these variations should be
mandatory in Spanish families in which a minimum of 3
breast and/or ovarian cancer patients are present in 2
generations of the same parental branch.
Both Hartman et al. (20 ) and Bunyan et al. (22 )
suggested that, in their study populations, MLPA may be
marginally more cost effective as a first line of screening
in the clinical setting. This may also be true in the Spanish
population. However, we think that the main advantage
of using MLPA as a first line is not cost effectiveness, but
rather the fact that it will greatly reduce the reporting time
for as much as 8.2% of the positive families. However, we
should stress the importance of excluding the presence of
sequence variations at the target sequences to interpreting
an MLPA profile correctly.
We found 8 different BRCA1 LGRs in our population.
Of these, only 1 (del exon 8–13) has been described
outside Spain. The spectrum of LGRs observed in our
population has 2 interesting features. First, 2 alterations
involve sequences at the 3 end of the gene (del exon
23–24 and del exon 1–24). This finding suggests that, in
addition to the high density of intragenic alu repeats (2 )
and the upstream BRCA1 pseudogene (11 ), downstream
sequences may render the BRCA1 locus particularly prone
to rearrangements (in this regard, it is interesting to note
that alu repeats are highly frequent in a 35-kb genomic
region downstream of BRCA1 exon 24). Second, we de-
tected a considerable proportion of genomic amplifica-
tions (3 of 8), whereas most BRCA1 LGRs identified in
other populations are deletions (22, 23).
Three alterations (del exon 14, dup exon 20, and exon
21–22 amplification) were observed twice in unrelated
families from the Castile region. Del exon 14 was fully
characterized in both families, demonstrating it to be
identical at the molecular level. Dup exon 20 and exon
21–22 amplification could not be fully characterized at the
molecular level, but nonetheless, the study suggests the
existence of recurrent variations associated with the geo-
graphical origin of the families.
Taken together, our data indicate the presence of a high
proportion of country-specific alterations and genetic
diversity among subpopulations, in agreement with a
previous study by our consortium showing that a high
proportion of the BRCA1 point variations found in Spain
are country specific, with local founder effects (22 ).
Our data support the view that BRCA1 LGRs are
equivalent to point variations in terms of cancer risk. First,
the proportion of LGRs was higher in HBOC (8%) than in
HBC (1.3%) families, indicating a strong association with
ovarian cancer risk. Second, the 4 site-specific breast
cancer families with LGR identified in our study had
defects downstream of exon 18, supporting a tendency for
families with variations toward the 3 end of the gene to
have a lower incidence of ovarian cancer (18, 24).
We have not characterized the breakpoints in 5 LGRs
(del exon 1–24, dup exon 19–20, dup exon 20, exon 21–22
amplification, and del exon 23–24). The molecular char-
acterization of genomic rearrangements is time consum-
ing and technically demanding, especially if genomic
amplifications or deletions involve regions outside the
BRCA1 locus. If the molecular characterization of a sus-
pected LGR is not feasible, genetic testing laboratories
should develop alternative strategies to exclude the pos-
sibility of false positives. In the present study, all genomic
rearrangements have been confirmed by an alternative set
of MLPA probes (BRCA1 probe set P087). To further
exclude the presence of false positives, additional molec-
ular evidence (long-range PCR or real-time PCR) has been
obtained in all positive samples, with the exception of the
sample carrying a whole-gene BRCA1 deletion. This dou-
ble-checking confirms the presence of a genomic rear-
rangement in those cases in which breakpoints have not
been characterized.
The possibility of commonly occurring variants at or
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near the probe binding site is a well-known source of
MLPA false positives (as identified by the company in the
assay inserts). Therefore, depending on the variants
present in a given population, the screening may become
troublesome. Our data indicate, however, that this is not
a major concern in our population. Bearing in mind all of
these considerations, we think that MLPA is a feasible
method to scan for BRCA1 LGRs in a genetic diagnostic
laboratory.
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